In addition to traditional backbone therapy for infant ALL, this study, AALL0631, is the first trial to incorporate novel targeted therapy, Flt3 inhibitor- CEP-701 (lestaurtinib) (47, 48). Here, FLT3 is linked to acute lymphoblastic leukemia.